- Home
- MOLN vs TLSI Comparison
MOLN vs TLSI Comparison
Compare MOLN & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOLN
- TLSI
- Stock Information
- Founded
- MOLN 2004
- TLSI 2010
- Country
- MOLN Switzerland
- TLSI United States
- Employees
- MOLN N/A
- TLSI N/A
- Industry
- MOLN
- TLSI Medical Specialities
- Sector
- MOLN
- TLSI Health Care
- Exchange
- MOLN Nasdaq
- TLSI Nasdaq
- Market Cap
- MOLN 142.6M
- TLSI 150.0M
- IPO Year
- MOLN 2021
- TLSI N/A
- Fundamental
- Price
- MOLN $3.75
- TLSI $4.60
- Analyst Decision
- MOLN Hold
- TLSI Strong Buy
- Analyst Count
- MOLN 1
- TLSI 5
- Target Price
- MOLN $4.00
- TLSI $10.90
- AVG Volume (30 Days)
- MOLN 5.2K
- TLSI 102.3K
- Earning Date
- MOLN 11-05-2025
- TLSI 11-13-2025
- Dividend Yield
- MOLN N/A
- TLSI N/A
- EPS Growth
- MOLN N/A
- TLSI N/A
- EPS
- MOLN N/A
- TLSI N/A
- Revenue
- MOLN $856,302.00
- TLSI $35,990,000.00
- Revenue This Year
- MOLN N/A
- TLSI $56.79
- Revenue Next Year
- MOLN $1,000.00
- TLSI $54.15
- P/E Ratio
- MOLN N/A
- TLSI N/A
- Revenue Growth
- MOLN N/A
- TLSI 45.50
- 52 Week Low
- MOLN $3.36
- TLSI $3.42
- 52 Week High
- MOLN $7.60
- TLSI $5.88
- Technical
- Relative Strength Index (RSI)
- MOLN 51.77
- TLSI 45.93
- Support Level
- MOLN $3.69
- TLSI $4.41
- Resistance Level
- MOLN $3.85
- TLSI $5.10
- Average True Range (ATR)
- MOLN 0.15
- TLSI 0.30
- MACD
- MOLN 0.01
- TLSI -0.07
- Stochastic Oscillator
- MOLN 37.27
- TLSI 20.59
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.